$RAPP News

Rapport Therapeutics’ RAP-219 Hits Phase II Goals in Bipolar Mania Trial

Rapport Therapeutics (RAPP) Could Be 62% Below Fair Value Following Phase 2 Mania Data

Rapport Therapeutics (RAPP) Stock Gets Fair Value Boost After RAP 219 Bipolar Mania Data

Why Rapport Therapeutics (RAPP) Is Up 5.8% And What's Next

Jones Trading Maintains Buy on Rapport Therapeutics, Raises Price Target to $82

Wells Fargo Maintains Overweight on Rapport Therapeutics, Lowers Price Target to $50

Guggenheim Maintains Buy on Rapport Therapeutics, Raises Price Target to $70

Rapport Therapeutics, Inc. (RAPP) Discusses Phase II Bipolar Mania Trial Results and Business Update Transcript

Rapport’s epilepsy drug finds surprising success in bipolar trial

Rapport Therapeutics Gains 4% on Positive Bipolar Mania Trial Results: “First New Mechanism” in Decades

Why Is Rapport Therapeutics Stock Trading Higher Today?

HC Wainwright & Co. Reiterates Buy on Rapport Therapeutics, Maintains $66 Price Target

Rapport Therapeutics soars over 50% as bipolar mania drug meets trial goals

Rapport Therapeutics Shares Rise Over 50% Premarket as RAP-219 Meets Phase 2 Bipolar Mania Trial Endpoints

Rapport Therapeutics Announces Positive Topline Results from its Phase 2 Trial of RAP-219 for the Treatment of Bipolar Mania

BTIG Maintains Buy on Rapport Therapeutics, Raises Price Target to $89

Rapport Therapeutics Announces That Topline Results From Its Phase 2 Trial Of RAP-219 In Adults With Acute Bipolar Mania Met Primary Endpoint

Rapport Therapeutics (RAPP) Stock Seems Pricey Following A 29% Monthly Slide

UBS Initiates Coverage On Rapport Therapeutics with Buy Rating, Announces Price Target of $71

Wolfe Research Initiates Coverage On Rapport Therapeutics with Outperform Rating, Announces Price Target of $50